2 models fit Accelerant Holdings Class A Common Shares and they disagree: 0 of 2 land within 15% of the average.
Two or more of our models back this value.
Large discount(i)Silver77
Valued as a growth company: Discounted cash flow and P/E comparison.
ACCE opinionAccelerant Holdings Class A Common Shares (ARX)
Fair value (2 models)
$31.52
ACCE price target
$20.50
Rating
Undervalued
Horizon
12 months
Fair value published on 24 Oct 2026, 17:04 CEST; previously $22.66 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 24 Oct 2026, 17:04 CEST.
Price used: $19.77 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
37.3% below
+59.4% to fair value
ACCE score
75
out of 100
Analysts
0% buy
6 covering
1-year return
+59.4%
Dividend yield
0.00%
Accelerant Holdings Class A Common Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Accelerant Holdings runs a managing general agency and insurance platform that places specialty risk, including binding authority for underwriters, and earns commissions and fees on the premium it writes. Its edge is distribution: it sits between carriers and niche brokers, so growth comes from adding programs and capacity rather than building a retail sales force. Revenue grew 57.2% in the latest reported figures, with a 65.1% gross margin and a 15.6% operating margin, which is an unusually high combination for a broker. The trailing P/E is not meaningful at 0.0, but the forward P/E of 22.2 is the number to test against the growth rate. The ROE of -222.0% reflects a small equity base relative to earnings and is worth digging into before any conclusion is drawn from it, since it can mask either a capital-light model or fragile balance sheet support.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
moderate
Insider selling outweighs buying
Last 10 disclosed insider trades total $1.28M in sales against $0.41M in buys. Modest in size, but the net direction is selling.
moderate
Sequential revenue decline
Revenue fell 7.1% quarter over quarter even though it grew 57.2% year over year, so the recent trajectory is softer than the headline growth suggests.
moderate
Earnings driven by one-off swing
Net margin is -127.5% with ROE at -222.0%, while operating margin is +15.6%. The gap points to large non-operating or non-recurring items, so reported earnings growth of 800.0% is not a clean read on the business.
AI research notes
AI-assisted·How I use AIWritten Oct 24, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 57.2% year over year, and the five-year average annual growth rate is 70.9%.
Free cash flow over the last twelve months reached $404M, and the stock offers a 9.4% free cash flow yield.
The diluted share count fell 12.2% last fiscal year, and the latest earnings per share beat expectations by 100.0%.
Why it could disappoint
Net margin is -127.5% and return on equity is -222.0%, so the business is still losing money heavily.
The forward P/E of 21.1x sits well above the sector median of 11.7x.
None of the 6 analysts rate the stock Buy or Strong Buy, and the analyst mean target of $20.25 sits only 2.4% above the price.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 11, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where ARX's valuation models land
Price
$19.77
Model fair value
$31.52
Model range
$10.81 to $56.37
Fair value $31.52
Price $19.77
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores